Lv43
450 积分 2025-07-01 加入
Glucagon receptor antagonism requires further mechanistic attention on α-cell physiology
1天前
已完结
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
6天前
已完结
IL-6: from its discovery to clinical applications
6天前
已完结
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial
14天前
已完结
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
14天前
已完结
Glucagon in type 2 diabetes: Friend or foe?
15天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
1个月前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
1个月前
已完结
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
1个月前
已完结
皖公网安备34019202002308
